Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | ARAMIS: darolutamide in patients with nmCRPC

Neal Shore, FACS, MD, Carolina Urologic Research Center, Myrtle Beach, SC, provides an outline of the Phase III ARAMIS trial (NCT02200614) of darolutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). Patients receiving darolutamide twice daily reached the primary and secondary endpoints of metastasis-free survival and overall survival (OS) respectively. Incidences of adverse events (AEs) such as fractures and cognitive impairment were additionally lower compared to other androgen receptor inhibitors (ARIs). This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.